Last reviewed · How we verify
Docetaxel Polymeric Micelles for Injection
Docetaxel inhibits microtubule dynamics by stabilizing microtubules and preventing their depolymerization.
Docetaxel Polymeric Micelles for Injection, developed by Jiangsu Simcere Pharmaceutical Co., Ltd., is a novel formulation of docetaxel designed to improve its pharmacokinetics and safety profile. Currently in Phase I and Phase II trials, it targets advanced solid tumors and malignant ascites. The drug aims to enhance the therapeutic index of docetaxel by reducing systemic toxicity while maintaining or improving efficacy.
At a glance
| Generic name | Docetaxel Polymeric Micelles for Injection |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This leads to cell cycle arrest at the G2/M phase and apoptosis in cancer cells.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Prostate cancer
Common side effects
- Neutropenia
- Anemia
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: